{"id":"etonogestrel-releasing-implant-contraceptive","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Irregular bleeding or amenorrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Acne"},{"rate":"5","effect":"Breast tenderness"},{"rate":"5","effect":"Weight gain"},{"rate":"3-5","effect":"Mood changes"},{"rate":"1-2","effect":"Insertion site pain or infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etonogestrel is a synthetic progestin released continuously from a subdermal implant over 3 years. It acts on the hypothalamic-pituitary-ovarian axis to inhibit the LH surge necessary for ovulation, while also increasing cervical mucus viscosity to impede sperm transport. This dual mechanism provides highly effective contraception with typical use failure rates below 1%.","oneSentence":"Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:00.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06775626","phase":"EARLY_PHASE1","title":"Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel","status":"SUSPENDED","sponsor":"Maíta Poli de Araújo","startDate":"2025-04-01","conditions":"Menstrual Symptoms","enrollment":40},{"nctId":"NCT04047875","phase":"PHASE4","title":"Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2020-09-15","conditions":"Breakthrough Bleeding","enrollment":114},{"nctId":"NCT05742503","phase":"","title":"Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-03-30","conditions":"Progesterone, Contraceptive Methods","enrollment":80},{"nctId":"NCT00620035","phase":"PHASE3","title":"A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Contraception","enrollment":301},{"nctId":"NCT00620464","phase":"PHASE3","title":"A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Contraception","enrollment":108},{"nctId":"NCT02594462","phase":"PHASE4","title":"Contraception in Women With Sickle Cell Disease","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2015-01","conditions":"Sickle Cell Disease","enrollment":29},{"nctId":"NCT03336346","phase":"","title":"Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-11-15","conditions":"Contraceptive Usage, HIV Infections, Drug Interaction","enrollment":148},{"nctId":"NCT00828542","phase":"NA","title":"Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-07","conditions":"Breastfeeding, Contraception","enrollment":40},{"nctId":"NCT01666912","phase":"PHASE4","title":"Postpartum Etonogestrel Implant for Adolescents","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-08","conditions":"Adolescence, Contraception, Postpartum","enrollment":96},{"nctId":"NCT02414919","phase":"","title":"Duration of Use of Highly Effective Reversible Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-04-01","conditions":"Pregnancy","enrollment":13880},{"nctId":"NCT02469454","phase":"PHASE4","title":"Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2015-06","conditions":"Contraception, Newborn, Child Development","enrollment":100},{"nctId":"NCT00847587","phase":"PHASE4","title":"Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-01","conditions":"Complications; Contraceptive, Female Lactation","enrollment":69},{"nctId":"NCT02416687","phase":"PHASE4","title":"Etonogestrel Implant and Postpartum Insertion","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT01392157","phase":"PHASE4","title":"Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-06","conditions":"Contraceptive Usage, Bleeding Due to Intrauterine Contraceptive Device","enrollment":300},{"nctId":"NCT01388582","phase":"PHASE4","title":"The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-04","conditions":"Underweight","enrollment":40},{"nctId":"NCT01384331","phase":"PHASE4","title":"New Treatments for Troublesome Bleeding in Implanon Users","status":"UNKNOWN","sponsor":"Family Planning Association New South Wales","startDate":"2011-07","conditions":"Menstrual Problem","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["implanon"],"phase":"marketed","status":"active","brandName":"etonogestrel-releasing implant contraceptive","genericName":"etonogestrel-releasing implant contraceptive","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus. Used for Contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}